Siglecs as targets for therapy in immune-cell-mediated disease.
about
Variation of Neisseria gonorrhoeae lipooligosaccharide directs dendritic cell-induced T helper responsesDevelopmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expressionThe clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaSiglecs as sensors of self in innate and adaptive immune responsesSiglecs and immune regulationThe Inflammatory Role of Platelets via Their TLRs and Siglec ReceptorsGlycotherapy: new advances inspire a reemergence of glycans in medicineAntigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activationPorcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophagesLow copy numbers of DC-SIGN in cell membrane microdomains: implications for structure and function.From a library of MAG antagonists to nanomolar CD22 ligands.In vivo targeting of B-cell lymphoma with glycan ligands of CD22.Glycomic analysis of human mast cells, eosinophils and basophils.Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.Multifarious roles of sialic acids in immunity.Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles.Siglec-mediated regulation of immune cell function in disease.In silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages.Click and pick: identification of sialoside analogues for siglec-based cell targetingMultivalent ligands for siglecs.Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages.On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.Potential targeting of siglecs, mast cell inhibitory receptors, in interstitial cystitis.Role of siglecs and related glycan-binding proteins in immune responses and immunoregulationTargeting B lymphoma with nanoparticles bearing glycan ligands of CD22A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.Expression and preliminary functional analysis of Siglec-F on mouse macrophages.A Siglec-like sialic-acid-binding motif revealed in an adenovirus capsid proteinDirect Enzymatic Branch-End Extension of Glycocluster-Presented Glycans: An Effective Strategy for Programming Glycan Bioactivity.Effect of anti-siglec-f antibody and reactive oxygen species blocking on histamine release in urinary bladder of ovalbumin-treated mice.Immunologic mapping of glycomes: implications for cancer diagnosis and therapySiglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Refolded recombinant Siglec5 for NMR investigation of complex carbohydrate bindingTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.Copresentation of antigen and ligands of Siglec-G induces B cell tolerance independent of CD22.Glycobiology simplified: diverse roles of glycan recognition in inflammationStructural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8
P2860
Q21090511-0F1FC5D5-7043-4DAA-A67B-C6CDE3E18434Q24634555-771C12CC-1D10-4A68-A066-7CC13FADFE46Q26783425-8317F542-4F01-4421-AE37-4F560A30F75FQ26829757-5B095474-0303-42E7-91BC-254CD7F7BBA0Q26992091-BDE26C5F-AA31-4625-8727-0545E522CDC7Q27004467-745B2C91-41F5-4F74-9E27-5D0F17117792Q27027997-C8D7D4E1-A2FF-4EBF-B6FC-4031607C8606Q27301034-63C24E11-28FF-4B94-A08F-0D657B0DE413Q28290873-CFA91B7E-D6D0-4956-9198-D11587F2267BQ28477167-E3466F4A-D073-4AE3-855C-FC7263CDBDE5Q30584406-0E3E238B-F5CC-4487-BBCC-B5EC0F15324BQ31032076-9F0393E4-452D-4B17-AF48-6113DA2CBC30Q33931886-3570B166-5EF0-4376-B562-3ED5B3EBC465Q33949464-F1B5CF6B-383B-4D18-B0C8-95EB7B3D8DF0Q33974526-79E8D6DB-B435-44FD-A832-A8758D149417Q34270155-844B8C85-4287-42AC-ACD6-AD7DD3B9E9ACQ34312462-0DEF625B-2DBC-4159-9B07-9DA3F497EC4BQ34314957-F0783B7F-07DC-4698-B554-1305B35D2D0EQ34411323-8219260B-A796-42A2-9385-C0FE8C26F773Q34434838-9245995F-07D9-4734-993C-3DD5FE31F398Q34449574-2708F464-77CC-4376-9CC0-8A122652FE26Q34470480-9EDBD341-02BD-48DC-985F-C3960E92165BQ34663064-381F1B32-7497-43C0-B0C3-A728616A7E56Q34677175-890A4864-C622-421B-A5B3-8EE3B60017F6Q35112704-07C702B6-1428-4542-B713-098C6E290486Q35164415-5F45332C-696D-42EC-9011-1159E4C0D022Q35403620-008A92C8-6B55-4AED-A43F-F6CBD0FB61CCQ35674073-3CFF613F-A3FE-48F5-8A81-FACAF7BDCF75Q35946412-931FE542-5EA6-4C75-8F86-93EA81B14E3EQ36056053-94E69384-E3BC-4594-A337-ADD59307BF21Q36236170-4D2B2DB7-02C5-4D7D-9E9C-7673355864D3Q36313180-2E18ECF4-B680-49E3-8684-C28AD2F996DEQ36543504-2A026779-9857-4F9A-AE0B-51077F123A2BQ36655884-7C4BCE64-4487-49EA-A593-B060CB9BE3E3Q36672921-98740EF5-DC60-4688-91AE-B0E04C592110Q36979140-018A1A2E-C180-4AC1-A737-F1E4213EE002Q36996975-12975D5E-3C4D-459D-A926-7D2EE90F07BCQ37075803-431098D0-CE50-4219-A2E7-328E17B5EE80Q37111287-B8CA8E03-73D9-4CB9-AFB8-48A82BDBD0BDQ37126813-B3B8838E-7A90-437F-A940-C5B6739E42B1
P2860
Siglecs as targets for therapy in immune-cell-mediated disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Siglecs as targets for therapy in immune-cell-mediated disease.
@en
Siglecs as targets for therapy in immune-cell-mediated disease.
@nl
type
label
Siglecs as targets for therapy in immune-cell-mediated disease.
@en
Siglecs as targets for therapy in immune-cell-mediated disease.
@nl
prefLabel
Siglecs as targets for therapy in immune-cell-mediated disease.
@en
Siglecs as targets for therapy in immune-cell-mediated disease.
@nl
P2860
P1476
Siglecs as targets for therapy in immune-cell-mediated disease.
@en
P2093
James C Paulson
Mary K O'Reilly
P2860
P304
P356
10.1016/J.TIPS.2009.02.005
P577
2009-04-07T00:00:00Z